<?xml version="1.0" encoding="UTF-8"?>
<notes notes-type="version-changes">
 <sec sec-type="version-changes">
  <label>Revised</label>
  <title>Amendments from Version 1</title>
  <p>Revisions have been made to the manuscript based on reviewers' comments. The major changes are as follows: 
   <list list-type="bullet">
    <list-item>
     <p>In the Laboratory procedures section, we have added text to the manuscript to clarify on our genotyping assay.</p>
    </list-item>
    <list-item>
     <p>In the Results section, we have added information to highlight there was no significant difference between species A and C (predominant species) for most clinical signs reported, except for nasal discharge (p&lt;0.004) and difficulty in breathing (p&lt;0.019). In addition, we have also added a column on supplementary Table 1 to this effect. </p>
    </list-item>
    <list-item>
     <p>In the Discussion section, we have revised the first paragraph to illustrate the occurrence of HRV throughout the year is majorly sustained by the existence of simultaneous and successive mini-epidemics each caused by a different HRV type introduced into the community independently, assuming HRV types generate strong and lasting homotypic immunity and weak heterotypic immunity. </p>
    </list-item>
    <list-item>
     <p>These changes have been discussed further in the responses to the reviewers' specific comments. Other minor modifications include the addition of relevant references and text throughout the manuscript; supplementary table 1 has been amended.</p>
    </list-item>
    <list-item>
     <p>We have listed funding support from the DELTAS Africa Initiative, which was missed out in the version 1, and have added further description of the Wellcome Trust grant [107769/Z/10/Z] in the Grant information section.</p>
    </list-item>
   </list>
  </p>
 </sec>
</notes>
